Lung Neoplasm

Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors w… (full text at CIViC)

PMID 15329413 · Pao et al., 2004 · Open in CIViC

In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC)

PMID 20573926 · Maemondo et al., 2010 · Open in CIViC

Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.

PMID 15118125 · Paez et al., 2004 · Open in CIViC

In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.

PMID 24457318 · Fukihara et al., 2014 · Open in CIViC

There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate:… (full text at CIViC)

PMID 24736073 · Lim et al., 2014 · Open in CIViC

The goal of this study was to assess the frequency, overall survival, and classifying actionability of EGFR mutations in NSCLC within the Dutch population from 2013-2017. This study found that despite… (full text at CIViC)

PMID 34298851 · Koopman et al., 2021 · Open in CIViC

A 67 year old female with stage IIIA lung adenocarcinoma had right lobectomy followed by 4 cycles adjuvant chemotherapy with pemetrexed and cisplatin. Next generation sequencing found EGFR L858R mutat… (full text at CIViC)

PMID 35004270 · Wang et al., 2021 · Open in CIViC

In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhib… (full text at CIViC)

PMID 18408761 · Li et al., 2008 · Open in CIViC

In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R muta… (full text at CIViC)

PMID 16818618 · Shimamura et al., 2006 · Open in CIViC

A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells d… (full text at CIViC)

PMID 24893891 · Cross et al., 2014 · Open in CIViC

NanoTACs are peptide-derived PROTAC nanoparticles designed to target wild-type EGFR and the EGFR L858R/T790M variant. Unlike conventional tyrosine kinase inhibitors (TKIs), which temporarily inhibit E… (full text at CIViC)

PMID 41386736 · Jeong et al., 2026 · Open in CIViC

This phase 3 trial (NCT02151981) involved 419 patients with EGFR T790M mutant NSCLC who progressed after first-line EGFR inhibitor therapy (gefitinib, erlotinib, or afatinib) and were either treated w… (full text at CIViC)

PMID 27959700 · Mok et al., 2017 · Open in CIViC

A 76-year old woman (non-smoker) presented with stage IVB ling adenocarcinoma. Genetic testing was positive for EGFR L858R and T790M and osimertinib was given. Partial response was noted until progres… (full text at CIViC)

PMID 36313664 · Takamori et al., 2022 · Open in CIViC

A 67 year old female with stage IIIA lung adenocarcinoma had right lobectomy followed by 4 cycles adjuvant chemotherapy with pemetrexed and cisplatin. Next generation sequencing (NGS) found EGFR L858R… (full text at CIViC)

PMID 35004270 · Wang et al., 2021 · Open in CIViC

A 73-year old male (non-smoker) with advanced non-small-cell lung cancer (NSCLC) was found to have EGFR L858R mutation and MET amplification. The patient had a dramatic response to erlotinib and crizo… (full text at CIViC)

PMID 31864558 · Gainor et al., 2020 · Open in CIViC

In this phase III trial, 657 patients with locally advanced or metastatic NSCLC (Non-Small Cell Lung Cancer) harbouring EGFR mutations (exon 19 deletions or L858R) were treated with amivantamab plus c… (full text at CIViC)

PMID 37879444 · Passaro et al., 2024 · Open in CIViC

In this trial (MARIPOSA), 1074 patients with Non-Small Cell Lung Cancer harbouring exon 19 deletion or exon 21 L858R substitution were randomized (2:2:1) to receive lazertinib-amivantamab (n=429), osi… (full text at CIViC)

PMID 38942080 · Felip et al., 2024 · Open in CIViC

Deguelin exhibits a potent inhibitory effect in gefitinib-resistant H1975 cells with EGFR L858R/T790M mutation. Decreased phosphorylation was noted in cell lines treated with deguelin but not gefitini… (full text at CIViC)

PMID 32081857 · Gao et al., 2020 · Open in CIViC

EGFR L861 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a study of patients treated with erlotini… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplication… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a patient with metastatic adenocarcinoma of the lung harboring EGFR L861R mutation, MET D1028H and EGFR amplification, EGFR L861R was associated with acquired resistance to crizotinib monotherapy. … (full text at CIViC)

PMID 26845121 · Benderra et al., 2016 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A 43 year old female neversmoker lung adenocarcinoma patient with EGFR M766_A767insASV mutation was given erlotinib as first line treatment, and had progressive disease as best response with -3.9% cha… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors. Modeling suggested that EGFR M766Q could disrupt osi… (full text at CIViC)

PMID 31254668 · Castellano et al., 2019 · Open in CIViC

A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. Sequencing of circulating cell-free DNA showed EGFR L858R, an acqui… (full text at CIViC)

PMID 31254668 · Castellano et al., 2019 · Open in CIViC

A 65-year-old female with lung adenocarcinoma underwent NGS testing, revealing an EGFR-MACF1 fusion at the RNA level (mutation abundance: 17%) and EGFR amplification (copy number: 24.15). The fusion i… (full text at CIViC)

PMID 38595815 · Wang et al., 2024 · Open in CIViC

In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001).

PMID 22810899 · Johnson et al., 2013 · Open in CIViC

Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease … (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC